FF305 呈交日期： 2025年10月23日 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發 ...

Core Viewpoint - The pharmaceutical sector is experiencing significant pressure, with notable declines in stock prices for several companies [2]. Company Summaries - Rongchang Biopharmaceutical (09995.HK) has seen a decline of 11.2%, trading at 81.65 HKD [2]. - CStone Pharmaceuticals-B (09966.HK) has dropped by 8.2%, currently priced at 11.98 HKD [2]. - Junshi Biosciences (01877.HK) has decreased by 5.16%, with shares at 25 HKD [2]. - Kintor Pharmaceutical-B (02171.HK) has fallen by 4.63%, now at 16.07 HKD [2].

Group 1 - The pharmaceutical sector is under pressure, with notable declines in stock prices for companies such as Rongchang Biopharma (-11.2%), CStone Pharmaceuticals (-8.2%), Junshi Biosciences (-5.16%), and Kintor Pharmaceutical (-4.63%) [1] - Haitong International's recent report indicates that the pharmaceutical index has underperformed the broader market post the October Golden Week, primarily due to fluctuating tariffs and underwhelming external licensing expectations [1] - Guosen Securities believes that China's innovative drug industry shows a long-term positive development trend, particularly highlighted by explosive growth in BD transactions in recent years [1] Group 2 - The ESMO 2025 conference in Berlin featured 112 results, including 21 related to domestic new drug research [2] - Innovent Biologics announced a global strategic collaboration with Takeda Pharmaceutical to advance the development of next-generation immuno-oncology and antibody-drug conjugate therapies, with an upfront payment of $1.2 billion and potential milestone payments totaling up to $10.2 billion, bringing the total deal value to a maximum of $11.4 billion [2]

Group 1 - The pharmaceutical sector is under pressure, with notable declines in stock prices for companies such as Rongchang Biologics down 11.2% to HKD 81.65, and Innovent Biologics down 5.16% to HKD 25 [1] - Haitong International's recent report indicates that the pharmaceutical index has underperformed the market post the October Golden Week, primarily due to fluctuating tariffs and underwhelming external licensing expectations [1] - Guosen Securities believes that China's innovative drug industry shows a long-term positive development trend, particularly highlighted by explosive growth in BD transactions in recent years [1] Group 2 - The ESMO 2025 conference in Berlin featured 112 results, including 21 related to domestic new drug research [2] - Innovent Biologics announced a global strategic collaboration with Takeda Pharmaceutical to advance the development of next-generation immuno-oncology and antibody-drug conjugate therapies, with an upfront payment of USD 1.2 billion and potential milestone payments totaling up to USD 10.2 billion, bringing the total deal value to a maximum of USD 11.4 billion [2]

Group 1 - The pharmaceutical sector is under pressure, with notable declines in stock prices for companies such as Rongchang Biopharma (-11.2%), CStone Pharmaceuticals (-8.2%), Junshi Biosciences (-5.16%), and Kintor Pharmaceutical (-4.63%) [1] - Haitong International's recent report indicates that the pharmaceutical index has underperformed the broader market post the October Golden Week, primarily due to fluctuating tariffs and underwhelming external licensing expectations [1] - Guosen Securities believes that China's innovative drug industry shows a long-term positive development trend, particularly highlighted by explosive growth in BD transactions in recent years [1] Group 2 - The ESMO 2025 conference in Berlin featured 112 results, including 21 related to domestic new drug research [2] - Innovent Biologics announced a global strategic collaboration with Takeda Pharmaceutical to advance the development of next-generation immuno-oncology and antibody-drug conjugate therapies, with an upfront payment of $1.2 billion and potential milestone payments totaling up to $10.2 billion, bringing the total deal value to a maximum of $11.4 billion [2]

Summary of Key Points Core Viewpoint - On October 21, 32 Hong Kong-listed companies conducted share buybacks, totaling 14.32 million shares and an aggregate amount of HKD 58.19 million [1]. Group 1: Buyback Details - The company YunGongChang repurchased 2.10 million shares for HKD 8.22 million, with a highest price of HKD 3.980 and a lowest price of HKD 3.880, bringing its total buyback amount for the year to HKD 119 million [1][2]. - LianYiRong Technology-W repurchased 2.38 million shares for HKD 7.45 million, with a highest price of HKD 3.180 and a lowest price of HKD 3.100, totaling HKD 218 million in buybacks for the year [1][2]. - Mengniu Dairy repurchased 0.50 million shares for HKD 7.26 million, with a highest price of HKD 14.550 and a lowest price of HKD 14.460, accumulating HKD 451 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 21 was from YunGongChang at HKD 8.22 million, followed by LianYiRong Technology-W at HKD 7.45 million, and Mengniu Dairy also featured prominently [1][2]. - In terms of share quantity, LianYiRong Technology-W led with 2.38 million shares repurchased, followed by ShiSiYao Group and YunGongChang, each with 2.10 million shares [1][2]. Group 3: Additional Insights - KJ Pharma-B conducted its first buyback of the year, while Mengniu Dairy has made multiple buybacks totaling HKD 451 million [2]. - A detailed table of buybacks on October 21 includes various companies, their respective share counts, amounts, and price ranges, highlighting the active buyback environment in the Hong Kong market [2][3].

Group 1 - Multiple companies conducted share buybacks on October 21, 2025, with a total of 30 companies listed [1] - The largest buyback was by Cloud Factory (N23027), repurchasing 2.1 million shares for a total of 8.22 million yuan [1][2] - Other notable buybacks include Linklogis Technology (W09959) with 2.38 million shares for 7.45 million yuan and Mengniu Dairy (02319) with 500,000 shares for 7.26 million yuan [2] Group 2 - Cumulative buyback amounts for the year show Cloud Factory (N23027) has repurchased a total of 26.62 million shares, representing 5.786% of its total share capital [2] - Linklogis Technology (W09959) has repurchased 67.82 million shares, accounting for 3.174% of its total share capital [2] - Other companies with significant cumulative buybacks include Stone Four Pharmaceutical (02005) with 39.20 million shares (1.328%) and Kangchen Pharmaceutical (01681) with 6.50 million shares (7.637%) [2][3]

科济药业-B回购明细 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.10.21 | 25.00 | 17.150 | 16.990 | 426.98 | （文章来源：证券时报网） 证券时报·数据宝统计，科济药业-B在港交所公告显示，10月21日以每股16.990港元至17.150港元的价格 回购25.00万股，回购金额达426.98万港元。该股当日收盘价17.000港元，下跌1.51%，全天成交额 2104.25万港元。（数据宝） ...

Core Viewpoint - 科济药业-B (02171.HK) announced a share buyback of 250,000 shares at a cost of HKD 4.27 million on October 21 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 4.27 million [1] - The number of shares repurchased was 250,000 [1]

Core Viewpoint - Company Kintor Pharmaceutical (科济药业-B) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - Kintor Pharmaceutical plans to repurchase 250,000 shares at a total cost of approximately HKD 4.2698 million [1] - The buyback is scheduled for October 21, 2025, reflecting the company's strategy to enhance shareholder value [1]